Strides Pharma Acquires Watford Office from RO Group

In a significant move, Strides Pharma UK has acquired 56 Clarendon Road in Watford from RO Group for an undisclosed amount. This Watford office is set to become the new UK headquarters for the British arm of the multinational pharmaceutical giant, Strides Pharma Science. The sale, which concluded as an opportunistic transaction, allows RO Group to reinvest capital into other strategic assets across the Midlands and South of England.

Strides Pharma UK’s decision to relocate its headquarters to Watford marks a strategic step in strengthening its footprint within the UK pharmaceutical sector. This acquisition is pivotal as it complements the company’s long-term growth strategy in the UK. On the other hand, RO Group, which purchased the Watford property back in 2014, capitalises on a favourable real estate market to achieve a 40% premium over the 2025 valuation. This transaction underscores an evolving trend within the UK real estate market, where capital recycling into roadside and industrial assets has gained traction. RO Group received advisory support from Brasier Freeth and Womble Bond Dickinson in executing the deal.

The acquisition of 56 Clarendon Road by Strides Pharma underscores an evolution within the UK pharmaceutical landscape, demonstrating the company’s commitment to expanding its operational capabilities. Meanwhile, RO Group’s strategic sale opens new avenues for further investments, reflecting a dynamic approach to market opportunities.